The event will focus on UGN-102 (mitomycin) for intravesical solution for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and will highlight topline results from the Phase 3 ATLAS and pivotal ENVISION clinical trials.

For ENVISION, UroGen will provide complete response rate (the primary endpoint) from approximately 240 patients who completed the study; and for ATLAS, the predecessor to ENVISION, UroGen will provide complete response, durability, and safety data from approximately 280 patients that completed the study.

The program will also feature medical experts and a panel discussion on the treatment of LG-IR-NMIBC, followed by a live Q&A.